open access

Vol 19, No 2 (2016)
Reviews
Published online: 2016-07-29
Submitted: 2016-06-30
Accepted: 2016-07-13
Get Citation

Neuroendocrine neoplasms and somatostatin receptor subtypes expression

Jerzy Hankus, Romana Tomaszewska
DOI: 10.5603/NMR.2016.0022
·
Pubmed: 27479788
·
Nucl. Med. Rev 2016;19(2):111-117.

open access

Vol 19, No 2 (2016)
Reviews
Published online: 2016-07-29
Submitted: 2016-06-30
Accepted: 2016-07-13

Abstract

Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendo­crine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indi­cate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type. Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs’ pharmacotherapy in patients with unsatisfactory course.

Abstract

Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendo­crine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indi­cate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type. Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs’ pharmacotherapy in patients with unsatisfactory course.

Get Citation

Keywords

somatostatin, somatostatin receptor, SSTR, neuroendocrine neoplasm, NEN, expression

About this article
Title

Neuroendocrine neoplasms and somatostatin receptor subtypes expression

Journal

Nuclear Medicine Review

Issue

Vol 19, No 2 (2016)

Pages

111-117

Published online

2016-07-29

DOI

10.5603/NMR.2016.0022

Pubmed

27479788

Bibliographic record

Nucl. Med. Rev 2016;19(2):111-117.

Keywords

somatostatin
somatostatin receptor
SSTR
neuroendocrine neoplasm
NEN
expression

Authors

Jerzy Hankus
Romana Tomaszewska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl